explore -WSS

explore

author：entertainment 2025-10-01 17:05:44 - browse：779

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： What happened to the House vote on health price transparency?

Wikipedia

WSS

Assistant physicians can help address the primary care shortage

First U.S. drug developed to treat liver disease MASH is approved

FDA weighs limits of animal data in assessing artificial wombs

Change Healthcare outage fallout shows need for new oversight

Eli Lilly CEO gives to Mike Pence presidential super PAC

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

entertainment

explore

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

hotspot

In Memoriam: Notable people who died in 2023

How to save health care price transparency rules

In age of alternative facts, a scholarly course on calling out crap

Chamber of Commerce, DOJ clash in court over drug prices

What does generative AI mean for health care? We asked experts

President Biden's budget: Here's what you might have missed

Heart attack and stroke risk calculators need revising

Chamber of Commerce, DOJ clash in court over drug prices

Continuity nursing helped my family in our darkest PICU moments

Pushing for an NIH office for post

entertainment

Medicare coverage of Wegovy, once blocked, now looks possible

Free Covid tests will again be offered to all U.S. households

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

PBMs drew scrutiny in House hearing — and so did pharma

PBMs drew scrutiny in House hearing — and so did pharma

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

focus

focus

Wikipedia

Wikipedia